← Home / Insight Molecular Diagnostics Inc. (IMDX)
Stock Analysis

Insight Molecular Diagnostics Inc. (IMDX)

IMDX
IMDX · Healthcare • Diagnostics & Research
4.32 -2.81%
Track IMDX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IMDX price is:
52W Range Position
31%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-26 23:22 UTC
WOI Investment Thesis
Vulnerable
Current market structure would strengthen above 4.48. Holding above 4.28 preserves the current price structure.
⚖️
✓
Fundamentals
Weak / Negative / Pressured / Strong
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
4.28
↗
Break Above
No setup-specific trigger is available; nearest structural resistance is shown.
4.48
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
10
●
Financial Results
HIGH
IMDX reports financial results
(Exact name of Registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) 2 International Plaza Dr.
8-K Filing • SEC EDGAR
JUN
17
●
Management / Board
MEDIUM
IMDX board and management update
General The Annual Meeting was held on June 11, 2026, virtually via live webcast at https://edge.media-server.com/mmc/p/k94peovi .
8-K Filing • SEC EDGAR
MAY
13
●
Financial Results
HIGH
Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results: Fellow shareholders, We are pleased to report that customer demand for our kitted kidney transplant monitoring assay is growing and that we are moving quickly...
8-K Filing • SEC EDGAR
What's Driving IMDX?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is weak. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
⚠️ Key risk remains
Below 4.28
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
44.2
◎
How to read this setup
The nearest decision zone is framed by support around 4.28 and resistance near 4.48. The chart still needs to reclaim resistance to improve meaningfully, while any loss of support would keep weakness in control.
Price Chart
IMDX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-25
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$141.4M
Company size
EV
$126.9M
Debt-adjusted value
P/S
84.7
Very high
P/B
-6.8
Not meaningful
EV/Sales
76.0
Very high
EV/EBIT
-2.0
Not meaningful
P/FCF
-7.5
Not meaningful
FCF Yield
-13.29%
Cash return
Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
239,000
↘ Weak
📈 Net Income
-11.26M
↘ Negative
🧮 EPS (Basic)
-0.31
↘ Negative
Insight Molecular Diagnostics Inc.
Healthcare • Diagnostics & Research
You Might Also Like